Aspira Women's Health Inc. announced the formal launch of an updated OvaWatch ovarian cancer risk assessment test following the completion of all appropriate pre-launch activities. Adnexal masses develop near the uterus, usually in or around the ovaries, fallopian tubes, and neighboring connectivity tissues. Most adnexal masses do not pose a serious threat to the health of a woman and resolve on their own within a few months.

Other will require treatment or surgery. OvaWatch utilizes an AI-powered algorithm to assess malignancy risk of adnexal masses when initial clinical assessment indicates the mass is indeterminate or benign. With a negative predictive value of 99%, OvaWatch can help physicians confidently determine the appropriate care plan over time.